

PROTALEX, INC. (OTCQB: PRTX)

Protalex, Inc. is a clinical-stage biopharmaceutical company focused on the development of a class of drugs for treating autoimmune and inflammatory diseases including Rheumatoid Arthritis (RA) and Immune Thrombocytopenia (ITP). Protalex's lead product candidate, PRTX-100, is an immunomodulatory protein produced by bacteria that is known to modify aspects of the human immune system potentially leading to beneficial effects in autoimmune conditions. PRTX-100 has been granted Orphan Drug Designation for the treatment of ITP and its profile has been characterized in six completed and 2 ongoing clinical studies. In those trials in adult patients with active RA or ITP, PRTX-100 has been found to be generally safe and well tolerated at dose levels tested so far. Positive therapeutic effects have been seen in RA patients and ITP patients. Preclinical investigations are ongoing in other autoimmune conditions. There is potential for benefits compared to, or used in combination with, currently available treatments.

MANAGEMENT TEAM

Arnold P. Kling

President and Director

William E. Gannon, Jr., M.D.

Chief Medical Officer

RECENT NEWS

[Protalex Announces Data from Phase 1b Trial of PRTX-100 in Patients with Immune Thrombocytopenia Presented at the European Hematology Association 23rd Annual Meeting](#)

Jun 15 2018, 8:00 AM EDT

[Protalex Announces Lead Drug Candidate PRTX-100 Reduces Disease Activity in a Mouse Model of Myasthenia Gravis](#)

Jun 12 2018, 8:00 AM EDT

PROTALEX, INC.

131 Columbia Turnpike
Suite 1
Florham Park, NJ 07932
US

STOCK OVERVIEW

Symbol	PRTX
Exchange	OTCQB
Market Cap	3.43m
Last Price	\$0.0725
52-Week Range	\$0.045 - \$0.65
Fiscal Year End	December 31

12/17/2018 01:36 PM EST

INVESTOR RELATIONS

Lippert Heilshorn Associates
Anne Marie Fields
T: 212-838-3777
afields@lhai.com

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.